There are signs this approach is more successful, because while one pan-PI3K inhibitor (copanlisib/Aliqopa®) has been approved for relapsed follicular lymphoma [66], several isoform-specific inhibitors are now on the market; the PI3Kδ inhibitor idelalisib (Zydelig®) has been approved to target chronic lymphocytic leukemia (CLL) [67,68], the dual PI3Kδ/γ inhibitor duvelisib (Copiktra®) for relapsed or refractory CLL or small lymphatic lymphoma [69] and the PI3Kα inhibitor alpelisib (Piqray®) for HR+/HER2− advanced breast cancers with PIK3CA mutations [70]. Here, PIK3CB is linked to B-cell chronic lymphocytic leukemia.